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Abstract: Uterine perforation is an uncommon complication of intrauterine device insertion, 
with an incidence of one in 1,000 insertions. Perforation may be complete, with the device 
totally in the abdominal cavity, or partial, with the device to varying degrees within the uterine 
wall. Some studies show a positive association between lactation and perforation, but a causal 
relationship has not been established. Very rarely, a device may perforate into bowel or the urinary 
tract. Perforated intrauterine devices can generally be removed successfully at laparoscopy.
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Introduction
The aim of this review is to raise awareness of the circumstances in which perfora-
tion of the uterus by intrauterine devices (IUDs) can occur, the consequences of such 
perforations, and approaches to the management of suspected or actual perforation.
IUDs for contraception were first introduced by Richter1 in 1909 and were fur-
ther developed and deployed by Gräfenberg2 from 1929; there was then a resurgence 
with the modern era beginning in 1959 when flexible plastic IUDs were introduced.3 
Over the years, there have been many design modifications to improve effectiveness, 
acceptability, and safety.3 IUDs are a highly effective form of long-acting reversible 
contraception.
Use of intrauterine contraception worldwide is extensive: 13.9% of the world’s 
1.16 billion women aged 15–49, married or in a union, are using this method.4 Uptake 
of intrauterine contraception in China is even higher at 40.6% of their 269 million 
women aged 15–49.
Perforation of the uterus with IUDs was first described in the 1930s.5,6 Initially, there 
was denial that this could happen at the time of insertion, and it was postulated that 
devices were always forced through the uterine wall by uterine contractions.7 Consensus 
opinion is now that the most common mechanism is that the device is forced into or 
through the uterine wall at the time of insertion. Other terms such as “the wandering 
IUD”, the misplaced/displaced or missing IUD, ectopic IUD, migration, mislocation, 
transmigration, or translocation are therefore somewhat misleading. Less commonly, 
an IUD may penetrate into but remain within the myometrium; this is termed partial 
perforation.8 It appears that uterine contractions can sometimes force such a device 
through the uterine wall.
Although uterine perforation is a potentially serious complication of intra-
uterine contraceptive use, it is uncommon and it can often be asymptomatic. 
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Some cases are not identified until months or years after 
insertion.9–11 In one series, the longest interval that had 
elapsed between insertion and diagnosis was 43 years.12 
It is therefore important to put uterine perforation into con-
text. It very rarely leads to harmful sequelae, and it does not 
detract from the overall excellent safety record of IUDs.3
Literature search
A formal Medline search using the search terms uterine 
perforation, displac*, migrat*, perforat*, penetrat*, and 
translocat* together with intrauterine devices or intrauterine 
devices copper or intrauterine devices medicated gave 629 
English language results. Of these, 347 were found to be 
relevant. A similar search in EMBASE produced 418 relevant 
articles out of a total of 914. Further references were found 
within these articles.
Methodological considerations
Perforation of the uterus with an IUD is an uncommon 
phenomenon. Of the perforations that do occur, most do not 
cause long-term harm, although women are generally advised 
to go through a surgical removal procedure that has some 
risks. However, a significant harm associated with perforation 
may be the loss of the IUD’s contraceptive effect, resulting 
in unplanned, and often unwanted, pregnancy. Sometimes a 
perforation leads to trauma to internal structures; such cases 
are thought to be very rare.
Quantification of the incidence of perforation from large 
cohort studies has been done and is likely to be precise. How 
many of these perforations go on to become more compli-
cated is not known at all. Assessing the strength of risk fac-
tors for perforation is difficult. For instance, the definition 
of breast-feeding is imprecise, as many women reduce the 
amount they feed gradually over time and so it is not an “all or 
nothing” variable. Although one study with no association at 
all was found, there may be other negative studies that editors 
did not see fit to publish. There may also be smaller negative 
studies without the statistical power to give a valid result. 
There is therefore a potential risk of publication bias.
Apart from the data on incidence from cohort studies, 
much of the literature on this subject consists of isolated 
case reports; there are also some relatively small case series. 
This is the lowest quality of evidence in the hierarchy of 
evidence apart from “expert opinion”.13 This state of affairs 
means that when presenting the data there will inevitably 
be selection bias. Clinicians like to report unusual cases. In 
general, this bias will exaggerate the risks associated with 
uterine perforation.
The authors have not cited all case reports that were found 
in the literature. We have selected citations that describe each 
facet of the subject well, choosing for preference papers that 
have a case series rather than an individual case report, and 
papers that have reasonable literature reviews.
As this review is of necessity based mainly on findings 
from cohort studies, small series, and case reports, it cannot 
by its nature be a systematic review. However, the authors 
have attempted to collate current knowledge and opinion 
on this topic.
Terminology
Initially modern devices were “inert”, made entirely of metal or 
plastic. In the late 1960s, copper was added to plastic devices 
to increase their efficacy; a “frameless” copper-only device, 
GyneFix® (Contrel, Ghent, Belgium), also became available in 
1996. Hormone-releasing devices were developed to improve 
IUD efficacy and to reduce certain complications such as 
bleeding and pain. Copper-containing and hormone-releasing 
types of device are sometimes termed as “medicated” IUDs.
The abbreviation used for intrauterine devices known 
as a whole and for a conventional (nonhormone releasing) 
intrauterine device is IUD. Many types of IUD have been 
available over the years, latterly all with added copper. Several 
types of progestin-releasing IUD are now available; these will 
be referred to collectively as the IUS, the abbreviation for 
intrauterine system. Examples of past and currently available 
IUDs are shown in Figure 1.
Mechanism of perforation
Esposito et al14 postulated that two mechanisms of uterine 
perforation exist.
1. Immediate traumatic perforation
2. Later “secondary” perforation caused by gradual erosion 
through the myometrium
Confirmation of the latter mechanism has been achieved 
by serial computed tomography (CT) scans performed for 
nongynecologic purposes.15
In the early days of IUDs, insertion instruments were 
rigid and so perforation was more likely as a consequence.16 
An early version of the Birnberg bow had a perforation rate 
of one in 200 because of the rigidity of its inserter.17,18 With 
the Progestasert device, there was documented evidence of 
a reduction in perforation rate when the inserter was made 
more flexible and a uterine sound included in the package.19 
Nowadays, insertion tubes are made so that they are more 
flexible, but not so soft that they buckle easily. Other risk 
factors are use of a push-out insertion technique, or lack of 
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Uterine perforation by iUDs
an insertion tube, as was the case with the Dalkon Shield 
(Dalkon Corporation, Defiance, OH, USA).
Perforation can also happen with a uterine sound. Tra-
ditionally, metal sounds were used to measure the uterine 
cavity length. Plastic sounds are almost certainly safer as 
they are less rigid. Perforation of the uterus may occur when 
the uterus is being sounded, or a false track may be created 
which is then followed by the IUD.
The forces required to insert an IUD increase linearly 
with increasing inserter tube diameter.20 The force required 
to insert an IUD is generally 1.5–6.5 N. The forces generated 
physiologically within the uterus have been estimated to be 
theoretically as high as 50 N, sufficient to produce uterine 
perforation. This would explain the so-called “secondary” 
perforation as a consequence of embedment of a device. 
Except in cases of lactation or uterine atrophy (eg, due to 
long-term use of injectable progestins), it is thought that the 
forces required to cause perforation are higher than the forces 
needed to carry out insertion of an IUD.
Classification
Uterine perforation by IUDs was analyzed in detail by Zakin 
et al8 in a now-classic paper. The authors based their analysis 
on the 356 cases that they found in the literature in 1981. They 
described complete perforation, which is the device passing 
through all uterine layers – endometrium, myometrium, and 
serosa – to lie freely in the peritoneal cavity or enveloped by 
omentum or traveling into other rarer locations. In a minority 
of cases, the IUD penetrates only into the myometrium, which 
they termed partial perforation. Zakin et al8 made the impor-
tant points that missing removal threads do not necessarily 
imply that a device is incorrectly located and conversely that 
the threads may be visible when a device has perforated.
Three anatomical compartments are considered, disre-
garding the endometrium and serosa. These are as follows:
1. Uterine cavity
2. Myometrium
3. Peritoneal cavity
Partial perforation
The partially perforated device may be present in one, two, 
or all three anatomical compartments (Figure 2). A device 
with a type A perforation that is mainly situated in the uterine 
cavity (A1) will be easier to remove than one in which the 
IUD is mainly in the myometrium (A2). Indeed, removal of 
the latter can be difficult or even hazardous. Following a type 
B perforation the IUD lies entirely within the myometrium so 
that it cannot be seen either at hysteroscopy or laparoscopy. 
In a type C perforation the device has protruded into the peri-
toneal cavity but is still fixed in the myometrium. In a type 
D perforation, portions of the device are situated in all three 
compartments and a detailed assessment will be needed to 
Figure 1 Types of device.
Notes: (A) Ota Ring, (B) Birnberg Bow, (C) Majzlin Spring, (D) Lippes Loop, 
(E) GyneFix®, (F) copper-bearing device: CuTT380 slimline, and (G) Levonorgestrel 
intrauterine system: Mirena®. Types (A–D) all obsolete. images (A–D) courtesy of 
the Museum of Contraception and Abortion, vienna (www.muvs.org). images (E–G) 
courtesy of Durbin PLC, South Harrow, Middlesex, UK (www.durbin.co.uk).
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plan the mode of removal; D2 will be more complex to remove 
laparoscopically than D1.
A partial perforation may remain as such or it may convert 
into a complete perforation within a matter of days. This latter 
conversion is almost certainly due to uterine contractions 
pushing the device through the myometrium, the force needed 
depending on the shape of the device.
In a very unusual case, an IUD moved during pregnancy 
from a location in the lower uterine segment at 16 weeks’ 
gestation to the posterior fundal myometrium at the time of 
a 20-week miscarriage, to erosion into small bowel, found 
at laparoscopic sterilization 6 weeks later.21
Complete perforation
With a complete perforation of the uterus, the device may 
remain near the uterus or it may move within the abdominal 
cavity. Zakin et al8 found that the most common location 
for a completely perforated IUD is the pouch of Douglas. 
In nearly half of complete perforations, the device is 
located in the omentum, either loosely or adherent to it; 
in the latter case it may be so densely adherent that a por-
tion of omentum needs to be excised in order to remove 
the device. The threads of a completely perforated device 
will generally not be visible at the cervix by the time of 
follow-up.
embedment
Here, a device impinges on the endometrium with a force 
sufficient to cause pressure necrosis of underlying tissue and 
penetration into the superficial layers of the myometrium.22 
This phenomenon was seen in the past in women using the 
Majzlin spring device. When removal of an embedded device 
is attempted, trauma to tissues may occur. Great care is needed 
in cases of embedment if marked pain is caused at attempted 
removal. In one case, this caused a tear which resulted in a 2-liter 
hemorrhage.23
Incidence of perforation
Perforation of the uterus is uncommon: estimates in larger 
studies range from 0.4 to 1.6 per 1,000 insertions.9,19 
A nationwide prospective cohort study from New Zealand over 
a 10-year period found 28 perforations among 17,469 insertions 
of the Multiload® Cu375 IUD (Merck and Co., Inc., White-
house Station, NJ, USA), giving an incidence of 1.6 per 1,000 
insertions.9 A 3-year study by the same group found three per-
forations in 3,519 IUS insertions, giving an incidence of 0.9 per 
1,000.24 Both these studies represent “real-life” results, which 
give a truer picture than clinical  trials, especially when IUDs are 
being inserted by generalists. A Turkish hospital-based study 
of the T-380A IUD followed up women at 1 year and found an 
incidence of 2.2 per 1,000 insertions.25 Other studies that could 
not be so certain of the denominator have found lower rates; 
for instance a Finnish study calculated an incidence of 0.4 per 
1,000 sold devices.26 One study found a higher perforation rate 
in women using an IUD for the first time compared to women 
who had used the method previously.27
The long-standing debate about whether or not lactation 
is a risk factor for perforation with IUD insertion is described 
in the “Effect of insertion after pregnancy or during lactation” 
section.
Rates of perforation with any IUD may in part be 
influenced by the experience or the maintenance of skill of 
the operator. This was first mooted in a report from Singa-
pore, in which more perforations were seen in insertions 
by junior doctors or general practitioners than by experi-
enced gynecologists.7 In a large prospective cohort study 
of a copper IUD, doctors who had inserted fewer than ten 
IUDs during the 10-year study period (73% of the sample) 
had significantly higher perforation rates than those who 
had inserted between ten and 99.9 The European Active 
A2
A1
CB
D1
D2
Figure 2 Classification of partially perforated devices.
Notes: Type A: iUD present in uterine cavity and myometrium; Type B: iUD present 
entirely in myometrium; Type C: iUD present in myometrium and peritoneal cavity; 
Type D: iUD present in all three compartments. A copper-T device is depicted: any 
device can perforate the uterus. The size of the iUDs relative to the uterus has been 
slightly reduced for illustrative purposes. 
Abbreviation: iUD, intrauterine device.
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Surveillance (EURAS) study showed a higher perforation 
rate in insertions performed by clinicians who inserted 
fewer than 50 devices per year compared to those inserting 
50 or more per year.27
Although spontaneous reporting to national databases 
gives no feel for incidence due to the lack of a denominator, 
it is interesting to note that since its launch in 1996, there have 
been 114 reports of uterine perforation with the levonorgestrel 
IUS in the UK and 23 reports of such devices becoming 
embedded in the uterus, cervix, or other local tissues.28
Different device types
Perforation occurs with all device types, whether IUDs or 
IUSs (Figure 1). This includes frameless copper devices 
such as the GyneFix®.29–31 Perforation with the sharp tip of 
the GyneFix® stylet is potentially dangerous. A Cochrane 
review concluded that it is not known if the perforation 
rate for framed devices differs from frameless devices; one 
perforation was noted with GyneFix® in the studies reviewed 
(approximately 3,000 insertions) compared to none with the 
TCu380 framed device.32 The possibility has been raised that 
the GyneFix® anchoring knot may sometimes be located on 
the serosal surface of the uterus at the end of the insertion 
procedure,33 either because the thickness of the fundal myo-
metrium may in some cases be less than originally thought 
when GyneFix® was designed or because of thinning associ-
ated with long-term injectable progestin use.33,34
The type of framed device does not appear to be an influ-
encing factor in perforation rates.32 A large European cohort 
study (EURAS) found no clinically important differences 
in perforation rates between copper IUDs and the Mirena® 
IUS (Bayer Schering Pharma, Turku, Finland)27. There is no 
significant difference in perforation rates between Levosert® 
(Actavis, Hafnarfjörður, Iceland) and Mirena® IUSs.35 Early 
experience with newer low-dose levonorgestrel IUSs in clini-
cal trials has found a low crude incidence for complete or 
partial perforation (0%–0.03%).36,37
Risk factors for uterine perforation
Possible risk factors for perforation are listed below. However, 
the associations are either weak or inconsistent, so causality 
has not been demonstrated.
•	 Insertion by less experienced clinicians7,9,27
•	 Lactation: see the “Effect of insertion after pregnancy or 
during lactation” section
•	 Postpartum insertion (,6 months since delivery)25,27
•	 Lower parity25
•	 Higher number of previous abortions25
Age of the woman, history of dilation and curettage, and 
history of cesarean section have been found not to be associ-
ated with risk of uterine perforation.25,27
Effect of insertion after pregnancy 
or during lactation
The myometrium is softer when in the pregnant state and 
for a time afterwards, so is more vulnerable to being torn 
or punctured during instrumentation. Involution starts 
immediately after delivery and is rapid during the first week; 
by 2 weeks postpartum the uterus is contained within the 
pelvis; by about 4 weeks it is close to normal size. During 
full breast-feeding, estrogen levels are very low and the 
uterus is consequently small. As noted by Chi et al,38 IUD 
insertion is less painful in lactating women; this may be 
due to increased levels of β-endorphins.39 Perforation dur-
ing insertion at this time may be associated with little pain 
and may therefore be less likely to be noticed at the time 
of its occurrence.
Perforation in the postpartum period is generally rare. 
A Singaporean study in the 1960s (in which 2,487 of 8,977 
insertions were postplacental, ie, within 48 hours of delivery) 
recorded 93 perforations with the Lippes loop,7 where the per-
foration risk was perhaps high due both to its mode of release 
from its insertion tube and to its linear form if it did not 
conform to the shape of the uterine cavity. A later Californian 
study of insertions between 4 and 8 weeks postpartum showed 
a zero perforation rate with copper-7s and copper-Ts.40 In a 
Turkish study of copper T380A insertions, no perforations 
were observed at up to 6 weeks postpartum, but there were 
some when insertions were done after 6 weeks.41
The possibility that women who are lactating are more 
susceptible to perforation of the uterus when an IUD is 
inserted was first raised in 1966.16,42 This phenomenon was 
first investigated in a USA case-control study.43 This study 
showed a tenfold higher risk of perforation in women who 
were lactating at the time of IUD insertion compared to 
women with at least one live birth who were not lactating.
However, subsequent studies did not confirm this find-
ing. A multicenter 6-month follow-up study of 1,149 women 
who underwent copper-T 380A IUD insertion found no 
perforations in any of the women, breast-feeding or not 
breast-feeding.38
Analysis of 50 perforations reported to a Swedish 
insurance scheme register found that 27 of the women 
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(54%) were breast-feeding at the time of insertion.39 
A multicenter pharmacovigilance study found that 42% of 
women with IUS perforations were breast-feeding at the 
time of diagnosis.10 Also, in the EURAS study, a sixfold 
increase in risk of perforation associated with breast-
feeding was found.27
It is therefore not possible to give a definitive answer as 
to whether breast-feeding increases the risk of perforation. 
Current professional guidance gives no restriction on 
eligibility for IUD insertion after 4 weeks from delivery 
(postpartum), regardless of whether or not a woman is 
breast-feeding.44 For IUD insertion between 48 hours and 
4 weeks postpartum, WHOMEC45 and UKMEC46 assign cat-
egory 3 (risks generally outweigh advantages), but USMEC47 
assigns category 2 (advantages generally outweigh risks). In 
June 2015, the UK Medicines and Healthcare Products Regu-
latory Agency (MHRA) reviewed risk factors for perforation 
in light of the EURAS study results27 and concluded that 
the benefits of intrauterine contraception strongly outweigh 
the risks, including in those who are lactating or who have 
recently given birth.48
A systematic review of studies of surgical abortion and 
of miscarriage treated surgically, followed immediately by 
IUD insertion, showed perforation rates of one per 1,000 and 
0.9 per 1,000, respectively.49
Perforation sites
Perforation typically occurs into the uterorectal pouch 
(pouch of Douglas, cul-de-sac) with an anteverted uterus 
(Figure 3A) or the vesicouterine pouch if it is retroverted8 
(Figure 3B). Flexion of the uterus is also a factor. In one 
series, ultrasound examination of women with perforated 
IUDs showed a significant number with an acute angle of 
flexion of the uterine body in relation to the cervix.12 Perfo-
ration can also occur through the fundus, particularly if the 
uterus is in an axial orientation. It has also been reported to 
occur into the uterosacral ligament,50 broad ligament,50–52 
fallopian tube,53 and ovary.54 There is a report of IUD threads 
coming through the posterior fornix; after failed localization 
at laparoscopy, the IUD was removed by colpotomy.55 In 
one case, an IUD was found within an ovarian carcinoma.56 
Very rare sites have been described such as the anterior 
abdominal wall.57–59 There is one recorded case of sciatica 
after a posterior perforation.60
Most commonly the perforated device is found free 
in the peritoneal cavity. However, ultimately, it usually 
becomes attached to an organ, the bowel, the mesentery, or 
most commonly the omentum.61 Rarely, adhesion formation 
stimulated by a perforated device has resulted in intestinal 
obstruction.62
Perforation of the cervix is very rare and usually asymp-
tomatic. It is postulated that some degree of malposition of 
the device later results in force exerted by the vertical stem 
with slow, repetitive uterine contractions which gradually 
propel the device through the cervical tissues.8,63 Fortunately, 
removal can be relatively easy, usually by freeing the device 
initially by pushing it up toward the uterine cavity. There are 
reported cases of cervical perforation by the threads only,64 
which were found running in a fistulous tract along the 
ectocervix. One author postulated that this may have been 
preceded by trauma to the cervix from a tenaculum. How-
ever, this phenomenon can occur at sites other than where 
the tenaculum has been placed.65
Perforation into bowel
Perforation of large and small bowel, appendix, and rectum 
have been described.66–68 Removal sometimes has to involve 
resection of a segment of bowel. There are occasional reports 
of successful removal of an IUD per rectum by proctoscopy 
or colonoscopy.69,70 There is one case report of a perforated 
frameless IUD which apparently disappeared from the body, 
presumably via the intestine.71
Perforation with a modern T-shaped IUD has been known 
to cause partial intestinal obstruction. In a Danish case report, 
a perforation next to the sigmoid colon presented 5 years 
after insertion with thickening of the bowel wall causing 
acute abdominal pain.72 Zakin et al8 described the “stopper 
effect” whereby a device that had perforated into bowel leaves 
a defect in the bowel wall on removal through which bowel 
contents can pass, with resultant peritonitis. An exceedingly 
rare complication is fistula formation between different 
Posterior
perforation
Anteverted uterus Retroverted uterusA B
Anterior
perforation
Arrow indicates direction of travel of device
Figure 3 Diagrams showing direction of perforation in different uterine positions.
Notes: (A) Posterior perforation in an anteverted uterus; (B) Anterior perforation 
in a retroverted uterus.
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sections of bowel.73,74 A case of intestinal gangrene has also 
been reported.75
Perforation into the urinary tract
There are more than 70 cases of perforation involving the 
urinary tract reported in the literature.76 Perforation through 
to the bladder or ureter is an uncommon but regularly 
reported complication of IUD insertion. In some cases, 
there is urinary calculus formation around the device.77 
In one case report, the IUD was mainly situated in the 
urethra.78 There is one report of menouria (vesical menstrua-
tion) due to a vesicouterine fistula,79 and another report of 
formation of a colovesical fistula.80 There are three reported 
cases of retroperitoneal location of a perforated IUD with 
fibrosis around the right pelvic ureter leading to right 
 hydronephrosis.81,82 IUDs and associated bladder calculi can 
be removed cystoscopically.77,78
Localization of devices that have 
perforated
The first warning sign, and the most common reason for 
investigation, of possible uterine perforation is the finding 
of missing or lost IUD/IUS threads. The bedrock of diagno-
sis of perforation and localization of a perforated device is 
ultrasound scanning. Localization of devices is more precise 
using transvaginal scanning than with transabdominal scan-
ning. Ultrasound scanning is a better modality for identifying 
devices that are intrauterine rather than extrauterine. IUDs are 
easier to identify than IUSs on an ultrasound scan (Figure 4) 
as ultrasound imaging of the original (52 mg) levonorgestrel 
IUS (Mirena®) depends principally on the finding of an acous-
tic “shadow” rather than on visualizing the device itself. The 
inclusion of a silver ring at the junction between the vertical 
stem and side arms of the smaller dimension 13.5 mg IUS 
(Jaydess® and Skyla®; Bayer AG, Leverkusen, Germany) 
permits easier visualization of the device by ultrasound scan-
ning and distinguishes it from Mirena® on ultrasound scan 
and from Mirena® and other devices on X-ray.
In one series, ultrasound scanning failed to show the 
perforated device in more than half of cases.12 In this series, 
IUSs were more likely than IUDs to be missed. A perforated 
IUS that was ultimately shown on X-ray and CT scan had 
been missed by ultrasound scan alone.83 In another series, 
there was a noticeable discrepancy between the location of 
IUSs indicated by ultrasound imaging and subsequent actual 
location at surgery.84 Ultrasound can easily miss IUDs located 
in the upper abdomen.84 Both IUDs and IUSs are radiopaque, 
so if they are in the abdominal cavity they will always be 
visible on a whole-abdominal and pelvic X-ray view, but 
the precise location may still be uncertain (Figure 5); a CT 
Figure 4 Ultrasound scan images of intrauterine iUDs and an iUS.
Notes: (A) Sagittal view of framed iUD, (B) frameless iUD, and (C) sagittal view of 
iUS showing triangular acoustic shadow of device. Pictures courtesy of emeka Oloto.
Abbreviations: iUD, intrauterine device; iUS, intrauterine system.
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scan or magnetic resonance imaging will be able to localize 
devices of any type more accurately.85
Clinical features
A scenario that has occurred regularly, particularly in the 
more distant past, is that a clinician makes a presumption 
that “lost” threads are due to an IUD having been expelled, 
leading to long delays in diagnosis if an ultrasound scan, 
and if necessary an X-ray, is not performed to confirm the 
absence of the device. Sometimes another device is inserted 
so that both an intrauterine and an extrauterine device are 
present. Rarely, a perforation is not detected by ultrasound 
scanning and a second perforation occurs in the same 
individual.86,87
Assessment of the size and position of the uterus is 
essential before insertion of an IUD. Use of a uterine sound 
and traction with a tenaculum was suggested in 196616 and 
has become part of routine practice. This is particularly 
important where there is sharp ante- or retroversion of the 
uterus, acute ante- or retroflexion, or a severe mismatch of 
flexion and version12 (Figure 3); if these angulations are not 
straightened with traction using a tenaculum then perforation 
is probably more likely.88 Setting the flange on the introducer 
accurately to the uterine cavity length as measured with the 
sound is also important.
Uterine perforation can occur with the sound, with the 
device itself, or with both. If the sound or inserter pass further 
than one would normally expect (over 10–11 cm) and if no 
resistance is felt, then this should be regarded as suspicious 
and the instrument or device immediately withdrawn from 
the uterus and the procedure abandoned. If perforation is 
suspected following insertion of the device, an ultrasound 
scan may be carried out immediately if the facilities and skills 
are available, or arranged via an imaging department.
In around 90% of cases, perforation is not recognized at 
the time of IUD insertion.9,10 The threads are generally still 
emerging from the cervical os at the end of the procedure, 
even with a complete perforation. Sometimes perforation is 
suspected between the time of insertion and follow-up, due 
to persistent symptoms, mainly mild lower abdominal pain. 
One of the main purposes of follow-up about 6 weeks after 
insertion is to exclude expulsion and perforation. In most 
cases of perforation the threads are not visible at 6 weeks. 
However, not all women attend for this follow-up examina-
tion. In a few cases in which the IUD is located in the pouch 
of Douglas, the device can be palpated on vaginal or rectal 
examination.8
Many instances of perforation are diagnosed later than 
the follow-up examination, often because of the occurrence 
of a pregnancy, which may be ectopic.89 Other indicators of 
perforation are “lost” threads and persistent lower abdomi-
nal pain. In the 10-year New Zealand cohort study, over 
half of perforations were diagnosed more than 1 year after 
insertion.9
Figure 5 X-ray images of extrauterine iUD and iUS.
Notes: (A) Nova-T 380 iUD and (B) Mirena® iUS. Pictures courtesy of emeka Oloto.
Abbreviations: iUD, intrauterine device; iUS, intrauterine system.
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It should be borne in mind that when a perforated IUS lies 
close to the uterus, the woman may still experience amenor-
rhea from local progestin release;90 the IUS may also have an 
adequate “remote” contraceptive effect.91 A perforated IUS 
has been reported as a rare cause of secondary infertility.92,93 
In one case of IUS perforation, plasma levonorgestrel levels 
were higher from intraperitoneal release than are generally 
found from intrauterine release.94 In the Finnish study, women 
with perforations were less likely to become pregnant if their 
perforated device was an IUS rather than an IUD.11 However, 
a case report described a pregnancy occurring with a perfo-
rated IUS well within the expected 5-year IUS life span. It 
was removed from the omentum at cesarean section.95
When the bowel is perforated, a triad of symptoms has 
been described: abdominal pain, fever, and intermittent 
diarrhea.66 Rectal bleeding is also possible.96 Occasionally, 
bowel perforation is asymptomatic with discovery as an 
incidental finding, for instance at hysterectomy.97 When the 
urinary tract is perforated, symptoms may include dysuria, 
frequency, suprapubic pain, hematuria, and recurrent urinary 
tract infections. In one case, a perforated device was missed 
at hysterectomy and found subsequently in the right lower 
quadrant, 35 years after insertion and 14 years after the hys-
terectomy.98 In another case, an IUS was found in the abdo-
men despite the patient having had a vaginal hysterectomy 
and admissions to hospital on account of abdominal pain.83 
In the single reported case of right-sided sciatica, an IUD was 
resting on the lumbosacral plexus; it was postulated that the 
left side is protected by the sigmoid colon.60
Prevention of uterine perforation
Actions that can help to reduce the risk of uterine perforation 
associated with insertion of IUDs include:
•	 Avoidance of insertion or taking extra care (with special 
consent) from 48 hours to 4 weeks postpartum, especially 
if the woman is breast-feeding
•	 Use of a plastic rather than a metal sound
•	 Use of a suitable tenaculum and applying appropriate 
traction to it
•	 Provision of less rigid introducers by device manu-
facturers
•	 Accurate setting of the flange on the introducer according 
to the sounding distance and the specific instructions for 
the device
•	 A pull-back, rather than a push-out, release mechanism 
for the device
•	 Skilled insertion training for clinicians
•	 Insertion by experienced clinicians
There is no evidence that use of ultrasound control during 
the routine insertion of IUDs reduces the risk of perforation 
occurring. However, complex insertions (eg, after failed 
insertion elsewhere as a result of acute uterine ante- or 
retroversion or in cases of coexisting fibroids) are carried 
out under ultrasound guidance in many specialist centers, 
which will help to minimize the risk of uterine perforation. 
Ultrasound is also a very useful tool in verifying the location 
of an IUD/IUS after insertion, especially if there is concern 
about possible perforation.
Removal of devices that have 
perforated
It is conventional clinical practice to remove all devices that 
have completely perforated the uterine wall. Originally, this 
was considered vital99 as older, now obsolete, devices were 
“closed” (examples are Gräfenberg ring, Ota ring, Incon 
ring, Hall-Stone ring, Antigon and Birnberg bow – Figure 1) 
and a loop of bowel could pass through the device with 
resultant intestinal obstruction.100–103 Ring-shaped IUDs have 
continued to be used in China until recent years.
There is no such risk with newer, mainly T-shaped, devices 
(Figure 1). Many of these devices remain in the abdomen, 
for periods of years in some cases, without doing any harm 
before they are discovered. Some authorities have suggested 
that removal of a modern IUD is not warranted and that the 
risks of laparoscopy or even laparotomy are not justifiable 
when a woman with a perforated device is asymptomatic.104 
In one case report, a 62-year old woman who had a Lippes 
loop in her abdomen for 42 years was followed up without 
recourse to surgery.105 Another reason for conservative man-
agement would be a woman with complex medical problems 
who is deemed unfit for surgery.106
There is, however, the question as to whether the com-
ponents of IUDs (plastic frame and copper) or IUSs (plastic 
frame, progestin, silicone matrix and sleeve, and silver in 
the case of Jaydess®/Skyla®) induce peritoneal adhesions. 
A study on rabbits found that polyethylene foreign bodies 
elicited a peritoneal reaction with adhesion formation in 
most animals after 2 weeks.107 Several human studies have 
shown only local and delicate peritoneal adhesion formation; 
bands of adhesions that could cause bowel obstruction did 
not develop.104,108–110 An Israeli study showed no difference in 
the peritoneal reaction between IUDs and the IUS,110 but two 
other studies found that adhesion formation was more com-
mon with IUDs than the IUS.11,12 Adoni and Ben  Chetrit104 
were of the opinion that adhesions form during a limited 
period only; once formed, the authors suggested that they do 
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not develop further. However, in one series, adhesions were 
more common when the interval from insertion to surgical 
intervention was greater than 8 months.12 If they form, adhe-
sions are localized to the IUD/IUS site and prevent the device 
from moving further.109
The precise surgical details of removal of IUDs from 
the abdomen are outside the scope of this article. The first 
laparoscopic removal of an IUD took place in 1969.111 Lap-
aroscopic removals have been successfully performed in 
pregnancy.112 Perforated IUSs have been purposely left in situ 
during pregnancy113 or mistakenly thought to be intrauterine95 
and then removed at cesarean section.
Minimally-invasive laparoscopic removal is to be pre-
ferred, but when the removal is more complicated open 
laparotomy may be safer. In a 2012 systematic review of 
laparoscopies carried out for removal of perforated IUDs, 
64% were successful and 35% needed to be converted to 
laparotomy.114 The case series in that review were reported 
between 1972 and 2002, and the scope of laparoscopic 
surgery has certainly progressed in recent years. It could 
therefore be argued that a woman whose perforated IUD 
cannot be removed at initial laparoscopy should be referred 
to a surgeon with special skills in minimal access surgery, 
who may be more likely to remove a device successfully and 
safely than a general gynecologist. Occasionally “discretion 
is the better part of valor” and laparoscopy or laparotomy is 
abandoned when retrieval is unsuccessful in cases where the 
device has become densely adherent to, or buried in, vital 
structures. It should be noted that surgery to remove an IUD 
may itself cause adhesion formation.109 Laparoscopic removal 
is not feasible in type A and B perforations.115 However, type 
A perforations may well be amenable to removal of the device 
at hysteroscopy.
In certain cases, early laparoscopy is not the preferred 
approach. In a retrospective series of 95 cases of perforation, 
two devices were removed at cesarean section and one at post-
partum sterilization.116 Nitke et al84 noted that in several of 
their cases IUSs were located at a higher level in the abdomen 
at laparoscopy than had been indicated by the diagnostic erect 
X-ray. They postulated that IUSs attach to omentum which 
then shifts from pelvis to upper abdomen when the patient 
is in the Trendelenburg position for laparoscopy. This may 
also explain the more precise localization by CT scanning, 
during which the patient is supine. Some surgeons use X-ray 
imaging when the patient is positioned for surgery.
Healing of the myometrium after perforation is rapid. 
Often at laparoscopy a few days or weeks after IUD insertion 
and perforation, no scar is visible on the uterus to show the 
exit point.117 In the Kho and Chamsy12 series, the perforation 
site was identifiable in only one-third of cases. Zakin et al8 
concluded that scars would disappear by 2 months after per-
foration. This is, however, not invariably true and sometimes 
a scar does persist long-term.118
Medicolegal aspects
Perforation of the uterus is a recognized complication of 
IUD insertion. Provided that preinsertion counseling and 
assessment have been carried out, with provision of writ-
ten information, and the procedure is carried out using a 
safe technique and the patient then followed up with full 
documentation in the medical records, clinicians should 
not be vulnerable to litigation.119 Perforation is a risk each 
time IUD insertion is carried out in the same individual; 
risks should be explained at every procedure, not just the 
first.120
Consent for IUD insertion does not need to be in written 
form for nonanesthetized women, but a brief explanation of 
perforation along with the other complications is needed in 
order to obtain valid consent, including the information that 
the one in 1,000 risk of perforation is uncommon. This level 
of risk can be presented on a risk scale to make it easier to 
comprehend.121
Conclusion
While being an uncommon phenomenon, uterine perforation 
with an IUD is an important risk that must be explained to 
patients, prevented if possible by taking all steps to insert 
devices safely, and diagnosed and managed appropriately. 
Most cases are due to traumatic perforation that occurs at the 
time of insertion. However, “secondary” perforation can also 
occur by gradual erosion. A partial perforation may convert 
into a complete perforation.
Perforation occurs in one in 1,000 IUD or IUS inser-
tions and occurs with all types of devices. The evidence 
on perforation and lactation is conflicting: although some 
studies show a positive association, others do not and 
so a causal relationship has not been established. Most 
perforations are uncomplicated, with the device lying in 
a quiescent state in the abdomen. However, rarely other 
organs can be affected, either by direct trauma at the time 
of insertion or by subsequent erosion. Both the bowel and 
the urinary tract lie in close proximity to the uterus and 
can be affected.
Most cases are “silent” and not recognized at the time of 
insertion. IUSs are quite commonly missed when abdominal 
ultrasound is the only imaging modality used. Transvaginal 
 
O
pe
n 
Ac
ce
ss
 J
ou
rn
al
 o
f C
on
tra
ce
pt
io
n 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
4.
66
.7
5.
36
 o
n 
08
-A
ug
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Open Access Journal of Contraception 2016:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
29
Uterine perforation by iUDs
ultrasound scanning by the clinician searching for a 
“missing” device is usually the first line of investigation, 
but there is still much to be said for requesting a plain X-ray 
of abdomen and pelvis if the device is not located imme-
diately by ultrasound scan. When perforation is diagnosed, 
most devices can be and should be removed. This can most 
often be achieved by laparoscopy; sometimes laparotomy 
may be needed.
IUDs are remarkably simple, safe and cost-effective, long-
acting contraceptives. Overall, this review demonstrates the 
low morbidity associated with their use, even when uterine 
perforation occurs.
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